Unexplained weight loss (UWL), defined as a loss of more than 5% of the total body weight within a span of six months, is a common yet perplexing clinical scenario. It is often a harbinger of serious underlying pathology, necessitating a thorough evaluation. This article aims to provide a comprehensive approach to the evaluation of UWL in clinical practice.
The initial evaluation should focus on a detailed history and physical examination. It is important to ascertain the time frame, amount of weight loss, and associated symptoms. A meticulous review of systems can often hint at the underlying cause. The role of medications, diet, and lifestyle changes should be explored. Physical examination should be comprehensive, focusing on signs of systemic diseases.
Basic laboratory studies should be done, including complete blood count, metabolic panel, liver function tests, thyroid function tests, and tumor markers. Imaging studies, such as CT scans or ultrasound, should be considered based on the clinical suspicion. Endoscopic procedures might be necessary in cases with gastrointestinal symptoms.
If the initial workup is unrevealing, specialized evaluations might be warranted. These could include psychiatric evaluation for eating disorders or depression, rheumatologic workup for connective tissue diseases, or oncologic evaluation for suspected malignancies. The choice of further investigations should be guided by the clinical picture.
Patients with UWL should be closely monitored. If no cause is found despite a thorough evaluation, careful follow-up is essential as some conditions might manifest later. Any new symptoms or signs should prompt a re-evaluation.
Evaluating UWL is a complex task requiring a systematic approach. A meticulous history, physical examination, and judicious use of investigations can often lead to the diagnosis. Close follow-up is crucial in cases where the cause remains elusive. By adopting a comprehensive approach, clinicians can ensure optimal care for patients experiencing UWL.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation